TRUSYNERGY

Lobbying for BURRELL INTERNATIONAL GROUP (ON BEHALF OF AMO PHARMA) · Life Sciences R&D

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · posted Apr 14, 2026

Lobbying activity 1

Health Issues

Rare Disease Policy and FDA Policy.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem